Cerenome (PSTV) Cash & Current Investments (2010 - 2026)

Plus Therapeutics (PSTV) has reported Cash & Current Investments for 17 consecutive years, with $15.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 53.18% year-over-year to $15.1 million; the TTM figure through Mar 2026 stood at $15.1 million (up 53.18% YoY), while the FY2025 annual figure was $8.9 million, up 145.59% from the prior year.
• Cash & Current Investments advanced to $15.1 million in Q1 2026 per PSTV's latest filing, from $8.9 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $21.2 million in Q1 2022 and bottomed at $2.1 million in Q1 2024.
• Historically, Cash & Current Investments has averaged $11.6 million across 5 years, with a median of $10.9 million in 2023.
• Annual changes were most pronounced in 2024 — Cash & Current Investments tumbled 83.21% — and 2025, when it jumped 361.94%.
• Plus Therapeutics' Cash & Current Investments stood at $18.1 million in 2022, then plunged by 52.79% to $8.6 million in 2023, then tumbled by 57.84% to $3.6 million in 2024, then soared by 145.59% to $8.9 million in 2025, then jumped by 70.66% to $15.1 million in 2026.
• Business Quant data shows PSTV's Cash & Current Investments at $15.1 million in Q1 2026, $8.9 million in Q4 2025, and $16.6 million in Q3 2025.